A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Public ClinicalTrials.gov record NCT04935879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Study identification
- NCT ID
- NCT04935879
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2021 (Actual)
- Primary completion
- Jun 6, 2024 (Actual)
- Completion
- Jun 6, 2024 (Actual)
- Last update posted
- Dec 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama Children's and Women's Hospital | Mobile | Alabama | 36604 | — |
| University of South Alabama Mitchell Cancer Institute | Mobile | Alabama | 36604 | — |
| University of South Alabama Strada Patient Care Center | Mobile | Alabama | 36604 | — |
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| UC Irvine Health | Orange | California | 92868 | — |
| UCI Center for clinical research | Orange | California | 92868 | — |
| Uconn Health/Uconn John Dempsey Hospital/Neag Comprehensive Cancer Center/New England Sickle Cell | Farmington | Connecticut | 06030 | — |
| Hospital Pharmacy Services- Investigational Drug Services | Chicago | Illinois | 60612 | — |
| Rush University Medical Center Investigator Pharmacy | Chicago | Illinois | 60612 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Illinois Clinical Research Center (CRC) | Chicago | Illinois | 60612 | — |
| University of Illinois Hospital and Health Sciences System(UI Health) | Chicago | Illinois | 60612 | — |
| Dana-Farber Cancer Institute IDS Pharmacy | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Hospitals - Michigan Medicine | Ann Arbor | Michigan | 48109 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| DUMC Investigational Drug Services Pharmacy | Durham | North Carolina | 27710 | — |
| McGovern Medical School/Health Science Center Houston | Houston | Texas | 77030 | — |
| Memorial Hermann - TMC Investigational Drugs, IDS Pharmacy | Houston | Texas | 77030 | — |
| Memorial Hermann Hospital, Texas Medical Center - Clinical Research Unit (CRU) | Houston | Texas | 77030 | — |
| UT Physicians Comprehensive Sickle Cell Clinic | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04935879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04935879 live on ClinicalTrials.gov.